Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04213872 · ClinicalTrials.gov registry record · NA

Gene Expression, Meditative Movement, and Emotional Distress (GME)

A NA study of Cognitive Impairment, sponsored by Arizona State University.

Completed
Registry status
NA
Development phase
27
Enrollment target
1
Study location

NCT04213872: Completed NA study of Cognitive Impairment, sponsored by Arizona State University.

NCT04213872 is a NA study of Cognitive Impairment that has completed, run by Arizona State University. The registered enrollment target is 27 participants, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04213872, a NA study of Cognitive Impairment, has completed, sponsored by Arizona State University.

COMPLETED
Registry status
NA
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

Study Title: Gene Expression, Meditative Movement and Emotional Distress (GME) Background and Objectives: Breast cancer survivors (BCS) often report decrements in cognitive functioning. Cognitive impairment (CI) is generally understood as resulting from chemotherapy or radiation, but may also result from chronic emotional distress experienced by breast cancer patients and survivors. Meditation and exercise are both known to reduce stress, with growing evidence for the potential of each to also improve cognitive functioning in cancer patients and survivors. A Meditative Movement (MM) program (Qigong/Tai Chi Easy) offers the potential of combining both benefits of meditation and exercise for breast cancer survivors. This is a pilot study, testing the MM program to effect changes in cognitive functioning and associated symptoms/conditions such as anxiety, depression, sleep quality and using gene expression factors as biomarkers to potentially measure the molecular signature of these changes. Forty BCS will be consented and assigned to an intensive eight week MM program. Cognitive functioning and associated symptoms/conditions will be assessed before and after the 8-week MM program to examine the participants' behaviors and symptoms. Peripheral blood samples will be collected before and after the 8-week MM program and will be analyzed for gene expression changes. If successful, this study may provide preliminary data for a full powered randomized control trial if results show promise in the psycho-behavioral outcomes and genomic expression results.

Primary Outcome

Perceived Cognitive Impairments (CogPCI) is a patient self-report and validated subscale of the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-COG), 20 items. The range of values are 0-80 with lower scores signifying better outcomes.

Conditions Studied

Interventions

  • BEHAVIORAL Meditative Movement

Study Locations (1)

California

  • Robert and Beverly Lewis Family Cancer Care Center - Pomona

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2017-07-17
Est. Completion 2020-09-15
Phase NA
Arizona State University

187 total trials

What the finished NCT04213872 record still lists

NCT04213872 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Cognitive Impairment appearing as the primary indexed condition, and to 1 intervention - of which Meditative Movement is the first listed.

NCT04213872 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04213872 about?

NCT04213872 is a clinical study titled "Gene Expression, Meditative Movement, and Emotional Distress (GME)". Study Title: Gene Expression, Meditative Movement and Emotional Distress (GME) Background and Objectives: Breast cancer survivors (BCS) often report decrements in cognitive functioning. Cognitive impairment (CI) is generally understood as resulting from chemotherapy or radiation, but may also resu...

What is the current status of trial NCT04213872?

This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2017-07-17. Estimated completion is 2020-09-15.

What conditions does trial NCT04213872 study?

This clinical trial studies the following conditions: Cognitive Impairment.

What interventions are being tested in trial NCT04213872?

The interventions under investigation include: Meditative Movement (BEHAVIORAL).

Who is sponsoring clinical trial NCT04213872?

This trial is sponsored by Arizona State University, which has 187 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04213872 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cognitive Impairment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04213872's enrollment target sits among peer trials

27 87th of 105 higher than 18 of 105 other Cognitive Impairment trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00912041 · 27 participants · NA

    BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

  • NCT02847559 · 27 participants · Phase 2

    Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

  • NCT03380195 · 27 participants · NA

    Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness

  • NCT03384238 · 27 participants · Phase 1

    Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04213872, the US trial registry maintained by the National Library of Medicine. NCT04213872 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.